CARTI recently marked the first commercial clinical use of RenovoCath®, a patented, FDA-cleared device that enables local chemotherapy delivery near a tumor site rather than traditional systemic intravenous administration. The not-for-profit provider began leveraging RenovoCath® to treat a patient with sarcoma—a cancer that starts in the soft tissues or bones—in late June 2026 at CARTI Cancer Center Little Rock.
“Sarcoma can be challenging to treat because it often occurs in diverse locations and can be less responsive to systemic chemotherapy,” said Edgar St. Amour, MD, CARTI interventional radiologist. “Our experience using RenovoCath to deliver chemotherapy at a local level for pancreatic cancer and its potential to reduce toxicity encouraged us to identify other tumor types that could benefit from this innovative technology. We are encouraged by the early results we have observed and will continue to monitor the patient’s progress closely.”